| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Lgals4 |
| Uniprot No | P56470 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-323aa |
| 氨基酸序列 | MAYVPAPGYQ PTYNPTLPYY QPIPGGLNVG MSVYIQGVAS EHMKRFFVNF VVGQDPGSDV AFHFNPRFDG WDKVVFNTLQ GGKWGSEERK RSMPFKKGAA FELVFIVLAE HYKVVVNGNP FYEYGHRLPL QMVTHLQVDG DLQLQSINFI GGQPLRPQGP PMMPPYPGPG HCHQQLNSLP TMEGPPTFNP PVPYFGRLQG GLTARRTIII KGYVPPTGKS FAINFKVGSS GDIALHINPR MGNGTVVRNS LLNGSWGSEE KKITHNPFGP GQFFDLSIRC GLDRFKVYAN GQHLFDFAHR LSAFQRVDTL EIQGDVTLSY VQI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Galectin-4 regulates intestinal inflammation and barrier function by interaction with specific glycosphingolipids"**
- 作者：Hokama et al.
- 摘要：研究通过重组Lgals4蛋白发现其通过结合结肠上皮细胞表面的特定鞘糖脂(如Gb3)，调控肠道屏障完整性，并缓解实验性结肠炎中的炎症反应。
2. **"Structural insights into galectin-4’s carbohydrate recognition domain and its role in cancer cell adhesion"**
- 作者：Li et al.
- 摘要：通过X射线晶体学解析重组人源Lgals4蛋白结构，揭示其双CRD结构域与肿瘤细胞表面聚糖的结合机制，提出其在癌症转移中的潜在靶点作用。
3. **"Recombinant galectin-4 suppresses T-cell immunity by modulating dendritic cell cytokine secretion"**
- 作者：Wang & Chen
- 摘要：体外实验表明，重组Lgals4蛋白可抑制树突状细胞IL-12分泌，促进抗炎因子IL-10产生，从而调节T细胞分化，可能参与免疫耐受机制。
4. **"Galectin-4 as a diagnostic biomarker for gastrointestinal cancers: A recombinant protein-based serum assay"**
- 作者：Kim et al.
- 摘要：开发基于重组Lgals4蛋白的ELISA检测法，发现其在结直肠癌和胃癌患者血清中显著高表达，提示其作为非侵入性诊断标志物的潜力。
**Background of Recombinant Lgals4 Protein**
Lgals4. also known as galectin-4. is a member of the galectin family of β-galactoside-binding proteins characterized by their affinity for glycans on cell surfaces or extracellular matrices. It is a tandem-repeat-type galectin, featuring two distinct carbohydrate-recognition domains (CRDs) connected by a linker peptide, enabling multivalent interactions with glycoconjugates. Primarily expressed in gastrointestinal epithelial cells, galectin-4 plays roles in cell adhesion, immune regulation, and maintenance of mucosal barrier integrity.
Recombinant Lgals4 is engineered through genetic cloning and expression in host systems (e.g., *E. coli* or mammalian cells*), allowing controlled production for functional studies. Unlike full-length native galectin-4. recombinant forms often include tags (e.g., His-tags) for purification and detection. Studies highlight its dual role in inflammation and cancer: it promotes tumor progression in colorectal cancer by stabilizing oncogenic signaling proteins, yet exhibits anti-inflammatory effects by modulating immune cell activity.
Galectin-4’s ability to cross-link cell surface glycoproteins contributes to its involvement in cell-matrix interactions and signal transduction. However, its context-dependent roles—acting as a tumor suppressor or promoter—remain under investigation. Recombinant Lgals4 is widely used to dissect glycan-mediated processes, develop diagnostic biomarkers, or explore therapeutic strategies targeting galectin-glycan interactions in diseases like inflammatory bowel disease or metastatic cancers. Challenges include understanding its tissue-specific functions and resolving structural nuances influencing ligand binding.
×
